

Neuralstem, Inc.  
Form 8-K  
September 21, 2007

---

---

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): September 19, 2007**

---

**Neuralstem, Inc.**  
**(Exact name of registrant as specified in Charter)**

**Delaware  
(State or other  
jurisdiction of  
incorporation or  
organization)**

**000-1357459  
(Commission File No.)**

**52-2007292  
(IRS Employee  
Identification No.)**

**9700 Great Seneca Highway, Rockville, Maryland 20850  
(Address of Principal Executive Offices)**

**(301) 366-4841  
(Issuer Telephone number)**

---

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01**

**Other Events**

On September 19, 2007, Neuralstem, Inc. (“Company”) issued a press release announcing that the United States Patent and Trademark Office (“USPTO”) ruled in the Company’s favor with regard to certain claims made by StemCells, Inc. in their patent filings. The USPTO disallowed four (4) claims that were the basis of litigation initiated by StemCells, Inc. against the Company.

A copy of that press release is attached to this report as Exhibit 99.1.

**Item 9.01**

**Financial Statement and Exhibits.**

| <b><u>Exhibit<br/>Number</u></b> | <b><u>Description</u></b>              |
|----------------------------------|--|
| 99.1                             | Press Release Dated September 19, 2007 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By:

/s/ I. Richard Garr

---

I. Richard Garr  
Chief Executive Officer

Dated: September 19, 2007

---